<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p6" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_6{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_6{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_6{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_6{left:341px;bottom:30px;}
#t5_6{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_6{left:377px;bottom:30px;}
#t7_6{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_6{left:540px;bottom:30px;}
#t9_6{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_6{left:996px;bottom:873px;letter-spacing:-0.1px;}
#tb_6{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#tc_6{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#td_6{left:1091px;bottom:28px;letter-spacing:0.24px;}
#te_6{left:36px;bottom:778px;letter-spacing:-0.12px;word-spacing:0.02px;}
#tf_6{left:36px;bottom:748px;letter-spacing:-0.12px;}
#tg_6{left:36px;bottom:729px;}
#th_6{left:47px;bottom:729px;letter-spacing:-0.1px;word-spacing:0.01px;}
#ti_6{left:705px;bottom:729px;letter-spacing:-0.07px;}
#tj_6{left:864px;bottom:729px;letter-spacing:-0.08px;}
#tk_6{left:983px;bottom:729px;letter-spacing:-0.08px;}
#tl_6{left:47px;bottom:711px;letter-spacing:-0.09px;}
#tm_6{left:36px;bottom:693px;letter-spacing:-0.12px;}
#tn_6{left:36px;bottom:674px;}
#to_6{left:47px;bottom:674px;letter-spacing:-0.13px;word-spacing:0.01px;}
#tp_6{left:636px;bottom:674px;letter-spacing:-0.07px;}
#tq_6{left:795px;bottom:674px;letter-spacing:-0.08px;}
#tr_6{left:915px;bottom:674px;}
#ts_6{left:929px;bottom:674px;letter-spacing:-0.13px;word-spacing:0.05px;}
#tt_6{left:47px;bottom:656px;letter-spacing:-0.08px;}
#tu_6{left:508px;bottom:663px;}
#tv_6{left:36px;bottom:638px;letter-spacing:-0.13px;}
#tw_6{left:36px;bottom:619px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tx_6{left:36px;bottom:601px;letter-spacing:-0.1px;}
#ty_6{left:36px;bottom:583px;letter-spacing:-0.09px;word-spacing:0.01px;}
#tz_6{left:41px;bottom:564px;}
#t10_6{left:58px;bottom:564px;letter-spacing:-0.09px;}
#t11_6{left:36px;bottom:546px;letter-spacing:-0.12px;}
#t12_6{left:36px;bottom:528px;}
#t13_6{left:47px;bottom:528px;letter-spacing:-0.1px;word-spacing:0.02px;}
#t14_6{left:407px;bottom:528px;letter-spacing:-0.09px;}
#t15_6{left:519px;bottom:528px;letter-spacing:-0.08px;word-spacing:0.01px;}
#t16_6{left:702px;bottom:528px;letter-spacing:-0.09px;}
#t17_6{left:36px;bottom:509px;letter-spacing:-0.12px;}
#t18_6{left:36px;bottom:491px;letter-spacing:-0.09px;}
#t19_6{left:47px;bottom:473px;letter-spacing:-0.08px;}
#t1a_6{left:36px;bottom:454px;letter-spacing:-0.09px;}
#t1b_6{left:47px;bottom:436px;letter-spacing:-0.08px;}
#t1c_6{left:36px;bottom:418px;letter-spacing:-0.12px;}
#t1d_6{left:36px;bottom:399px;letter-spacing:-0.13px;word-spacing:-0.11px;}
#t1e_6{left:41px;bottom:381px;}
#t1f_6{left:58px;bottom:381px;letter-spacing:-0.09px;word-spacing:-0.1px;}
#t1g_6{left:464px;bottom:381px;letter-spacing:-0.08px;}
#t1h_6{left:548px;bottom:381px;letter-spacing:-0.08px;}
#t1i_6{left:641px;bottom:381px;letter-spacing:-0.09px;}
#t1j_6{left:713px;bottom:381px;letter-spacing:-0.12px;}
#t1k_6{left:764px;bottom:381px;letter-spacing:-0.09px;}
#t1l_6{left:930px;bottom:381px;letter-spacing:-0.09px;}
#t1m_6{left:58px;bottom:363px;letter-spacing:-0.43px;}
#t1n_6{left:36px;bottom:344px;letter-spacing:-0.09px;word-spacing:-0.01px;}
#t1o_6{left:47px;bottom:326px;letter-spacing:-0.08px;}
#t1p_6{left:36px;bottom:308px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1q_6{left:47px;bottom:289px;letter-spacing:-0.09px;}
#t1r_6{left:36px;bottom:271px;letter-spacing:-0.11px;}
#t1s_6{left:36px;bottom:253px;letter-spacing:-0.09px;}
#t1t_6{left:47px;bottom:234px;letter-spacing:-0.08px;}
#t1u_6{left:36px;bottom:216px;letter-spacing:-0.08px;}
#t1v_6{left:47px;bottom:198px;letter-spacing:-0.08px;}
#t1w_6{left:36px;bottom:179px;letter-spacing:-0.35px;}
#t1x_6{left:36px;bottom:161px;letter-spacing:-0.11px;word-spacing:0.03px;}
#t1y_6{left:41px;bottom:143px;}
#t1z_6{left:58px;bottom:143px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t20_6{left:467px;bottom:143px;letter-spacing:-0.08px;}
#t21_6{left:551px;bottom:143px;letter-spacing:-0.2px;word-spacing:0.1px;}
#t22_6{left:36px;bottom:124px;letter-spacing:-0.1px;}
#t23_6{left:36px;bottom:106px;}
#t24_6{left:47px;bottom:106px;letter-spacing:-0.09px;word-spacing:-0.01px;}
#t25_6{left:36px;bottom:88px;letter-spacing:-0.1px;}
#t26_6{left:36px;bottom:69px;}
#t27_6{left:47px;bottom:69px;letter-spacing:-0.11px;word-spacing:0.03px;}
#t28_6{left:1091px;bottom:57px;letter-spacing:-0.11px;}
#t29_6{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_6{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_6{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_6{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_6{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s4_6{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s5_6{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s6_6{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s7_6{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s8_6{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s9_6{font-size:14px;font-family:ArialMT_5tg;color:#000;}
.sa_6{font-size:17px;font-family:Webdings_k6;color:#000;}
.sb_6{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts6" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg6Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg6" style="-webkit-user-select: none;"><object width="1210" height="935" data="6/6.svg" type="image/svg+xml" id="pdf6" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_6" class="t s0_6">NCCN Guidelines Version 4.2024 </span>
<span id="t2_6" class="t s0_6">Head and Neck Cancers </span>
<span id="t3_6" class="t s1_6">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_6" class="t s2_6">® </span>
<span id="t5_6" class="t s1_6">(NCCN </span>
<span id="t6_6" class="t s2_6">® </span>
<span id="t7_6" class="t s1_6">), All rights reserved. NCCN Guidelines </span>
<span id="t8_6" class="t s2_6">® </span>
<span id="t9_6" class="t s1_6">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_6" class="t s3_6">NCCN Guidelines Index </span>
<span id="tb_6" class="t s3_6">Table of Contents </span>
<span id="tc_6" class="t s3_6">Discussion </span>
<span id="td_6" class="t s4_6">UPDATES </span>
<span id="te_6" class="t s4_6">Updates in Version 1.2024 of the NCCN Guidelines for Head and Neck Cancers from Version 2.2023 include: </span>
<span id="tf_6" class="t s5_6">HYPO-3 </span>
<span id="tg_6" class="t s6_6">• </span><span id="th_6" class="t s7_6" data-mappings='[[42,"fi"]]'>Treatment of primary and neck option, modiﬁed: Partial or total laryngopharyngectomy + </span><span id="ti_6" class="t s8_6">ipsilateral or bilateral </span><span id="tj_6" class="t s6_6">neck dissection </span><span id="tk_6" class="t s8_6">± hemi- or total </span>
<span id="tl_6" class="t s6_6">thyroidectomy and pretracheal and ipsilateral paratracheal lymph node dissection </span>
<span id="tm_6" class="t s5_6">HYPO-5 </span>
<span id="tn_6" class="t s6_6">• </span><span id="to_6" class="t s7_6" data-mappings='[[42,"fi"]]'>Treatment of primary and neck option, modiﬁed: Total laryngopharyngectomy + </span><span id="tp_6" class="t s8_6">ipsilateral or bilateral </span><span id="tq_6" class="t s6_6">neck dissection </span><span id="tr_6" class="t s8_6">± </span><span id="ts_6" class="t s6_6">hemi- or total thyroidectomy, </span>
<span id="tt_6" class="t s6_6">after ipsilateral or bilateral paratracheal lymph node dissection </span>
<span id="tu_6" class="t s9_6">i </span>
<span id="tv_6" class="t s5_6">NASO-A </span>
<span id="tw_6" class="t s6_6">• Note added: Hyperfractionation for locally advanced nasopharyngeal carcinoma: See RAD-A for irradiation dosing schedule. </span>
<span id="tx_6" class="t s5_6">NASO-B (1 of 3) </span>
<span id="ty_6" class="t s6_6">• Recurrent, Unresectable, Oligometastatic, or Metastatic Disease (with no surgery or RT option) </span>
<span id="tz_6" class="t sa_6"></span><span id="t10_6" class="t s7_6">Moved from other recommended regimens to preferred regimens: Cisplatin/gemcitabine + PD-1 inhibitor (eg, pembrolizumab or nivolumab) </span>
<span id="t11_6" class="t s5_6">SUPRA-2 </span>
<span id="t12_6" class="t s6_6">• </span><span id="t13_6" class="t s7_6" data-mappings='[[42,"fi"]]'>Treatment of primary and neck, option modiﬁed: </span><span id="t14_6" class="t s8_6">Endoscopic or </span><span id="t15_6" class="t s6_6">open partial supraglottic </span><span id="t16_6" class="t s7_6">laryngectomy + neck dissection (Also for SUPRA-5) </span>
<span id="t17_6" class="t s5_6">ETHM-1 </span>
<span id="t18_6" class="t s6_6">• Footnote removed: For SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies, systemic </span>
<span id="t19_6" class="t s7_6">therapy should be a part of the overall treatment. Consider a clinical trial and referral to a major medical center that specializes in these diseases. </span>
<span id="t1a_6" class="t s6_6">• Footnote i added: Ethmoid sinus tumors are rare and histopathologically diverse. Correct pathologic diagnosis is paramount to treatment decisions. </span>
<span id="t1b_6" class="t s7_6" data-mappings='[[84,"fi"]]'>Consider referral to a major medical center that specializes in these tumors for conﬁrmation of diagnosis. </span>
<span id="t1c_6" class="t s5_6">ETHM-2 </span>
<span id="t1d_6" class="t s6_6">• Primary Treatment </span>
<span id="t1e_6" class="t sa_6"></span><span id="t1f_6" class="t s7_6" data-mappings='[[36,"fi"]]'>Newly diagnosed T3, T4a options modiﬁed: Resection </span><span id="t1g_6" class="t s6_6">(preferred) </span><span id="t1h_6" class="t s6_6">or Systemic </span><span id="t1i_6" class="t s8_6">Induction </span><span id="t1j_6" class="t s8_6">chemo</span><span id="t1k_6" class="t s6_6">therapy (category 2B) </span><span id="t1l_6" class="t s6_6">or Concurrent systemic therapy/ </span>
<span id="t1m_6" class="t s6_6">RT </span>
<span id="t1n_6" class="t s6_6">• Footnote removed: Primary systemic therapy Induction chemotherapy options for newly diagnosed T3,T4a ethmoid sinus tumor include etoposide/ </span>
<span id="t1o_6" class="t s7_6" data-mappings='[[48,"fl"]]'>cisplatin (category 2B), or docetaxel/cisplatin/ﬂuorouracil (category 2B). </span>
<span id="t1p_6" class="t s6_6">• Footnote o added: Nonsurgical RT-based treatment is an option in selected patients with disease that has a major response to induction therapy short </span>
<span id="t1q_6" class="t s6_6">of a CR. </span>
<span id="t1r_6" class="t s5_6">MAXI-1 </span>
<span id="t1s_6" class="t s6_6">• Footnote removed: For SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies, systemic </span>
<span id="t1t_6" class="t s7_6">therapy should be a part of the overall treatment. Consider a clinical trial and referral to a major medical center that specializes in these diseases. </span>
<span id="t1u_6" class="t s6_6">• Footnote i added: Maxillary sinus tumors are rare and histopathologically diverse. Correct pathologic diagnosis is paramount to treatment decisions. </span>
<span id="t1v_6" class="t s7_6" data-mappings='[[84,"fi"]]'>Consider referral to a major medical center that specializes in these tumors for conﬁrmation of diagnosis. </span>
<span id="t1w_6" class="t s5_6">ADV-1 </span>
<span id="t1x_6" class="t s6_6">• Treatment of primary and neck </span>
<span id="t1y_6" class="t sa_6"></span><span id="t1z_6" class="t s7_6" data-mappings='[[16,"fi"]]'>PS2, option modiﬁed: Concurrent systemic therapy/RT </span><span id="t20_6" class="t s8_6">(preferred) </span><span id="t21_6" class="t s6_6">or RT </span>
<span id="t22_6" class="t s5_6">SALI-2 </span>
<span id="t23_6" class="t s6_6">• </span><span id="t24_6" class="t s7_6" data-mappings='[[91,"fi"]]'>Complete resection, adenoid cystic; intermediate or higher grade, category of evidence modiﬁed for RT for T1 disease: changed from 2B to 2A. </span>
<span id="t25_6" class="t s5_6">SALI-3 </span>
<span id="t26_6" class="t s6_6">• </span><span id="t27_6" class="t s7_6" data-mappings='[[62,"fi"]]'>Completely resected, adenoid cystic, category of evidence modiﬁed for RT: changed from 2B to 2A. </span>
<span id="t28_6" class="t s5_6">Continued </span>
<span id="t29_6" class="t sb_6">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
